#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Supportive care at home with plenty of rest , drinking plenty of fluids and using a pain reliever for aches and pains is adequate for recovery in most cases .
1-1	0-10	Supportive	abstract[1]	new[1]	_	_
1-2	11-15	care	abstract[1]	new[1]	_	_
1-3	16-18	at	abstract[1]	new[1]	_	_
1-4	19-23	home	abstract[1]|place[2]	new[1]|new[2]	_	_
1-5	24-28	with	abstract[1]|place[2]	new[1]|new[2]	_	_
1-6	29-35	plenty	abstract[1]|place[2]|event[3]	new[1]|new[2]|new[3]	_	_
1-7	36-38	of	abstract[1]|place[2]|event[3]	new[1]|new[2]|new[3]	_	_
1-8	39-43	rest	abstract[1]|place[2]|event[3]|abstract	new[1]|new[2]|new[3]|new	_	_
1-9	44-45	,	_	_	_	_
1-10	46-54	drinking	_	_	_	_
1-11	55-61	plenty	place[5]	new[5]	_	_
1-12	62-64	of	place[5]	new[5]	_	_
1-13	65-71	fluids	place[5]|substance	new[5]|new	_	_
1-14	72-75	and	_	_	_	_
1-15	76-81	using	_	_	_	_
1-16	82-83	a	abstract[8]	new[8]	coref	2-1[15_8]
1-17	84-88	pain	abstract|abstract[8]	new|new[8]	coref	2-3[14_0]
1-18	89-97	reliever	abstract[8]	new[8]	_	_
1-19	98-101	for	abstract[8]	new[8]	_	_
1-20	102-107	aches	abstract[8]|abstract	new[8]|new	_	_
1-21	108-111	and	abstract[8]	new[8]	_	_
1-22	112-117	pains	abstract[8]|abstract	new[8]|new	_	_
1-23	118-120	is	_	_	_	_
1-24	121-129	adequate	_	_	_	_
1-25	130-133	for	_	_	_	_
1-26	134-142	recovery	event[11]	new[11]	_	_
1-27	143-145	in	event[11]	new[11]	_	_
1-28	146-150	most	event[11]|abstract[12]	new[11]|new[12]	_	_
1-29	151-156	cases	event[11]|abstract[12]	new[11]|new[12]	_	_
1-30	157-158	.	_	_	_	_

#Text=A non- aspirin pain reliever should be used for children or adolescents under age 18 .
2-1	159-160	A	abstract[15]	giv[15]	_	_
2-2	161-165	non-	abstract[15]	giv[15]	_	_
2-3	166-173	aspirin	substance|abstract[14]|abstract[15]	new|giv[14]|giv[15]	_	_
2-4	174-178	pain	abstract[14]|abstract[15]	giv[14]|giv[15]	_	_
2-5	179-187	reliever	abstract[15]	giv[15]	_	_
2-6	188-194	should	_	_	_	_
2-7	195-197	be	_	_	_	_
2-8	198-202	used	_	_	_	_
2-9	203-206	for	_	_	_	_
2-10	207-215	children	person	new	coref	5-4[26_0]
2-11	216-218	or	_	_	_	_
2-12	219-230	adolescents	person	new	_	_
2-13	231-236	under	_	_	_	_
2-14	237-240	age	time[18]	new[18]	_	_
2-15	241-243	18	time[18]	new[18]	_	_
2-16	244-245	.	_	_	_	_

#Text=The public should be made aware that there are specific groups of people who appear to be at higher risk of more complicated or severe illness which include :
3-1	246-249	The	person[19]	new[19]	_	_
3-2	250-256	public	person[19]	new[19]	_	_
3-3	257-263	should	_	_	_	_
3-4	264-266	be	_	_	_	_
3-5	267-271	made	_	_	_	_
3-6	272-277	aware	_	_	_	_
3-7	278-282	that	_	_	_	_
3-8	283-288	there	_	_	_	_
3-9	289-292	are	_	_	_	_
3-10	293-301	specific	person[20]	new[20]	_	_
3-11	302-308	groups	person[20]	new[20]	_	_
3-12	309-311	of	person[20]	new[20]	_	_
3-13	312-318	people	person[20]|person	new[20]|new	coref	6-1[28_0]
3-14	319-322	who	_	_	_	_
3-15	323-329	appear	_	_	_	_
3-16	330-332	to	_	_	_	_
3-17	333-335	be	_	_	_	_
3-18	336-338	at	_	_	_	_
3-19	339-345	higher	abstract[22]	new[22]	coref	8-29[46_22]
3-20	346-350	risk	abstract[22]	new[22]	_	_
3-21	351-353	of	abstract[22]	new[22]	_	_
3-22	354-358	more	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-23	359-370	complicated	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-24	371-373	or	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-25	374-380	severe	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-26	381-388	illness	abstract[22]|abstract[23]	new[22]|new[23]	_	_
3-27	389-394	which	_	_	_	_
3-28	395-402	include	_	_	_	_
3-29	403-404	:	_	_	_	_

#Text=pregnant women ;
4-1	405-413	pregnant	person[24]	new[24]	_	_
4-2	414-419	women	person[24]	new[24]	_	_
4-3	420-421	;	_	_	_	_

#Text=infants , and young children particularly under age 2 ;
5-1	422-429	infants	person	new	_	_
5-2	430-431	,	_	_	_	_
5-3	432-435	and	_	_	_	_
5-4	436-441	young	person[26]	giv[26]	_	_
5-5	442-450	children	person[26]	giv[26]	_	_
5-6	451-463	particularly	person[26]|abstract[27]	giv[26]|new[27]	coref	6-3[29_27]
5-7	464-469	under	person[26]|abstract[27]	giv[26]|new[27]	_	_
5-8	470-473	age	person[26]|abstract[27]	giv[26]|new[27]	_	_
5-9	474-475	2	person[26]|abstract[27]	giv[26]|new[27]	_	_
5-10	476-477	;	_	_	_	_

#Text=people of any age with certain chronic health conditions ( including asthma or lung disease , heart disease , diabetes , kidney disease or some neurological conditions ) ;
6-1	478-484	people	person[28]	giv[28]	coref	7-1[39_28]
6-2	485-487	of	person[28]	giv[28]	_	_
6-3	488-491	any	person[28]|abstract[29]	giv[28]|giv[29]	_	_
6-4	492-495	age	person[28]|abstract[29]	giv[28]|giv[29]	_	_
6-5	496-500	with	person[28]|abstract[29]	giv[28]|giv[29]	_	_
6-6	501-508	certain	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-7	509-516	chronic	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-8	517-523	health	person[28]|abstract[29]|abstract|abstract[31]	giv[28]|giv[29]|new|new[31]	coref	9-23
6-9	524-534	conditions	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-10	535-536	(	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-11	537-546	including	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-12	547-553	asthma	person[28]|abstract[29]|abstract[31]|abstract	giv[28]|giv[29]|new[31]|new	_	_
6-13	554-556	or	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-14	557-561	lung	person[28]|abstract[29]|abstract[31]|object|abstract[34]	giv[28]|giv[29]|new[31]|new|new[34]	_	_
6-15	562-569	disease	person[28]|abstract[29]|abstract[31]|abstract[34]	giv[28]|giv[29]|new[31]|new[34]	_	_
6-16	570-571	,	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-17	572-577	heart	person[28]|abstract[29]|abstract[31]|abstract[35]	giv[28]|giv[29]|new[31]|new[35]	_	_
6-18	578-585	disease	person[28]|abstract[29]|abstract[31]|abstract[35]	giv[28]|giv[29]|new[31]|new[35]	_	_
6-19	586-587	,	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-20	588-596	diabetes	person[28]|abstract[29]|abstract[31]|abstract	giv[28]|giv[29]|new[31]|new	_	_
6-21	597-598	,	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-22	599-605	kidney	person[28]|abstract[29]|abstract[31]|abstract[37]	giv[28]|giv[29]|new[31]|new[37]	coref	9-10[52_37]
6-23	606-613	disease	person[28]|abstract[29]|abstract[31]|abstract[37]	giv[28]|giv[29]|new[31]|new[37]	_	_
6-24	614-616	or	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-25	617-621	some	person[28]|abstract[29]|abstract[31]|abstract[38]	giv[28]|giv[29]|new[31]|new[38]	_	_
6-26	622-634	neurological	person[28]|abstract[29]|abstract[31]|abstract[38]	giv[28]|giv[29]|new[31]|new[38]	_	_
6-27	635-645	conditions	person[28]|abstract[29]|abstract[31]|abstract[38]	giv[28]|giv[29]|new[31]|new[38]	_	_
6-28	646-647	)	person[28]|abstract[29]|abstract[31]	giv[28]|giv[29]|new[31]	_	_
6-29	648-649	;	_	_	_	_

#Text=people with severely compromised immune systems .
7-1	650-656	people	person[39]	giv[39]	coref	8-3[0_39]
7-2	657-661	with	person[39]	giv[39]	_	_
7-3	662-670	severely	person[39]|abstract[40]	giv[39]|new[40]	_	_
7-4	671-682	compromised	person[39]|abstract[40]	giv[39]|new[40]	_	_
7-5	683-689	immune	person[39]|abstract[40]	giv[39]|new[40]	_	_
7-6	690-697	systems	person[39]|abstract[40]	giv[39]|new[40]	_	_
7-7	698-699	.	_	_	_	_

#Text=Currently , people age 65 or older are the least likely to be infected with the pandemic influenza , but those who do get sick are also at high risk of developing serious complications , just as they are from seasonal flu .
8-1	700-709	Currently	_	_	_	_
8-2	710-711	,	_	_	_	_
8-3	712-718	people	person|abstract[42]	giv|new[42]	ana|coref|ana|coref	8-21|23-17[125_42]|8-21|23-17[125_42]
8-4	719-722	age	abstract[42]	new[42]	_	_
8-5	723-725	65	abstract[42]	new[42]	_	_
8-6	726-728	or	abstract[42]	new[42]	_	_
8-7	729-734	older	abstract[42]	new[42]	_	_
8-8	735-738	are	_	_	_	_
8-9	739-742	the	_	_	_	_
8-10	743-748	least	_	_	_	_
8-11	749-755	likely	_	_	_	_
8-12	756-758	to	_	_	_	_
8-13	759-761	be	_	_	_	_
8-14	762-770	infected	_	_	_	_
8-15	771-775	with	_	_	_	_
8-16	776-779	the	abstract[44]	new[44]	coref	13-6[0_44]
8-17	780-788	pandemic	animal|abstract[44]	new|new[44]	coref	10-13
8-18	789-798	influenza	abstract[44]	new[44]	_	_
8-19	799-800	,	_	_	_	_
8-20	801-804	but	_	_	_	_
8-21	805-810	those	person	giv	ana	8-38
8-22	811-814	who	_	_	_	_
8-23	815-817	do	_	_	_	_
8-24	818-821	get	_	_	_	_
8-25	822-826	sick	_	_	_	_
8-26	827-830	are	_	_	_	_
8-27	831-835	also	_	_	_	_
8-28	836-838	at	_	_	_	_
8-29	839-843	high	abstract[46]	giv[46]	_	_
8-30	844-848	risk	abstract[46]	giv[46]	_	_
8-31	849-851	of	_	_	_	_
8-32	852-862	developing	_	_	_	_
8-33	863-870	serious	abstract[47]	new[47]	_	_
8-34	871-884	complications	abstract[47]	new[47]	_	_
8-35	885-886	,	_	_	_	_
8-36	887-891	just	_	_	_	_
8-37	892-894	as	_	_	_	_
8-38	895-899	they	person	giv	coref	27-14[152_0]
8-39	900-903	are	_	_	_	_
8-40	904-908	from	_	_	_	_
8-41	909-917	seasonal	abstract[49]	new[49]	ana	9-7[0_49]
8-42	918-921	flu	abstract[49]	new[49]	_	_
8-43	922-923	.	_	_	_	_

#Text=( ( MM ) ) Is it known when the virus will become less virulent and cease becoming a major threat to health and of so when ?
9-1	924-925	(	_	_	_	_
9-2	926-927	(	_	_	_	_
9-3	928-930	MM	person	new	coref	12-3
9-4	931-932	)	_	_	_	_
9-5	933-934	)	_	_	_	_
9-6	935-937	Is	_	_	_	_
9-7	938-940	it	abstract	giv	_	_
9-8	941-946	known	_	_	_	_
9-9	947-951	when	_	_	_	_
9-10	952-955	the	abstract[52]	giv[52]	coref	10-12[59_52]
9-11	956-961	virus	abstract[52]	giv[52]	_	_
9-12	962-966	will	_	_	_	_
9-13	967-973	become	_	_	_	_
9-14	974-978	less	_	_	_	_
9-15	979-987	virulent	_	_	_	_
9-16	988-991	and	_	_	_	_
9-17	992-997	cease	_	_	_	_
9-18	998-1006	becoming	_	_	_	_
9-19	1007-1008	a	_	_	_	_
9-20	1009-1014	major	_	_	_	_
9-21	1015-1021	threat	_	_	_	_
9-22	1022-1024	to	_	_	_	_
9-23	1025-1031	health	abstract	giv	_	_
9-24	1032-1035	and	_	_	_	_
9-25	1036-1038	of	_	_	_	_
9-26	1039-1041	so	_	_	_	_
9-27	1042-1046	when	_	_	_	_
9-28	1047-1048	?	_	_	_	_

#Text=( ( KM ) ) It is impossible to predict when the pandemic H1N1 virus will become less virulent .
10-1	1049-1050	(	_	_	_	_
10-2	1051-1052	(	_	_	_	_
10-3	1053-1055	KM	quantity	new	coref	13-3
10-4	1056-1057	)	_	_	_	_
10-5	1058-1059	)	_	_	_	_
10-6	1060-1062	It	abstract	new	cata	10-6[0_56]
10-7	1063-1065	is	_	_	_	_
10-8	1066-1076	impossible	_	_	_	_
10-9	1077-1079	to	abstract[56]	new[56]	_	_
10-10	1080-1087	predict	abstract[56]	new[56]	_	_
10-11	1088-1092	when	_	_	_	_
10-12	1093-1096	the	abstract[59]	giv[59]	coref	14-19[75_59]
10-13	1097-1105	pandemic	plant|abstract[59]	giv|giv[59]	coref	14-20
10-14	1106-1110	H1N1	object|abstract[59]	new|giv[59]	coref	12-12
10-15	1111-1116	virus	abstract[59]	giv[59]	_	_
10-16	1117-1121	will	_	_	_	_
10-17	1122-1128	become	_	_	_	_
10-18	1129-1133	less	_	_	_	_
10-19	1134-1142	virulent	_	_	_	_
10-20	1143-1144	.	_	_	_	_

#Text=Diagram showing antigenic shift .
11-1	1145-1152	Diagram	person	new	_	_
11-2	1153-1160	showing	_	_	_	_
11-3	1161-1170	antigenic	abstract[61]	new[61]	_	_
11-4	1171-1176	shift	abstract[61]	new[61]	_	_
11-5	1177-1178	.	_	_	_	_

#Text=( ( MM ) ) Is there a significant risk of H1N1 mutating and becoming more deadly ?
12-1	1179-1180	(	_	_	_	_
12-2	1181-1182	(	_	_	_	_
12-3	1183-1185	MM	person	giv	coref	15-3
12-4	1186-1187	)	_	_	_	_
12-5	1188-1189	)	_	_	_	_
12-6	1190-1192	Is	_	_	_	_
12-7	1193-1198	there	_	_	_	_
12-8	1199-1200	a	abstract[63]	new[63]	_	_
12-9	1201-1212	significant	abstract[63]	new[63]	_	_
12-10	1213-1217	risk	abstract[63]	new[63]	_	_
12-11	1218-1220	of	abstract[63]	new[63]	_	_
12-12	1221-1225	H1N1	abstract[63]|abstract	new[63]|giv	coref	14-21
12-13	1226-1234	mutating	_	_	_	_
12-14	1235-1238	and	_	_	_	_
12-15	1239-1247	becoming	_	_	_	_
12-16	1248-1252	more	_	_	_	_
12-17	1253-1259	deadly	_	_	_	_
12-18	1260-1261	?	_	_	_	_

#Text=( ( KM ) ) Influenza viruses constantly change through a process called antigenic drift .
13-1	1262-1263	(	_	_	_	_
13-2	1264-1265	(	object[67]	new[67]	coref	14-1[71_67]
13-3	1266-1268	KM	quantity|object[67]	giv|new[67]	coref	16-3
13-4	1269-1270	)	object[67]	new[67]	_	_
13-5	1271-1272	)	object[67]	new[67]	_	_
13-6	1273-1282	Influenza	abstract|object[67]	giv|new[67]	coref	14-2
13-7	1283-1290	viruses	object[67]	new[67]	_	_
13-8	1291-1301	constantly	_	_	_	_
13-9	1302-1308	change	_	_	_	_
13-10	1309-1316	through	_	_	_	_
13-11	1317-1318	a	abstract[68]	new[68]	coref	14-5[72_68]
13-12	1319-1326	process	abstract[68]	new[68]	_	_
13-13	1327-1333	called	_	_	_	_
13-14	1334-1343	antigenic	abstract[69]	new[69]	_	_
13-15	1344-1349	drift	abstract[69]	new[69]	_	_
13-16	1350-1351	.	_	_	_	_

#Text=All influenza viruses undergo this process but there is no way to predict if , when and how the pandemic H1N1 virus will shift .
14-1	1352-1355	All	object[71]	giv[71]	coref	22-8[119_71]
14-2	1356-1365	influenza	abstract|object[71]	giv|giv[71]	coref	18-18
14-3	1366-1373	viruses	object[71]	giv[71]	_	_
14-4	1374-1381	undergo	_	_	_	_
14-5	1382-1386	this	abstract[72]	giv[72]	_	_
14-6	1387-1394	process	abstract[72]	giv[72]	_	_
14-7	1395-1398	but	_	_	_	_
14-8	1399-1404	there	_	_	_	_
14-9	1405-1407	is	_	_	_	_
14-10	1408-1410	no	_	_	_	_
14-11	1411-1414	way	_	_	_	_
14-12	1415-1417	to	_	_	_	_
14-13	1418-1425	predict	_	_	_	_
14-14	1426-1428	if	_	_	_	_
14-15	1429-1430	,	_	_	_	_
14-16	1431-1435	when	_	_	_	_
14-17	1436-1439	and	_	_	_	_
14-18	1440-1443	how	_	_	_	_
14-19	1444-1447	the	abstract[75]	giv[75]	_	_
14-20	1448-1456	pandemic	plant|abstract[75]	giv|giv[75]	coref	18-9
14-21	1457-1461	H1N1	object|abstract[75]	giv|giv[75]	coref	16-8
14-22	1462-1467	virus	abstract[75]	giv[75]	_	_
14-23	1468-1472	will	_	_	_	_
14-24	1473-1478	shift	_	_	_	_
14-25	1479-1480	.	_	_	_	_

#Text=( ( MM ) ) Are the current anti-flu vaccines effective and how sufficient is the current supply ? Can you explain how these anti-virus vaccine work and any possible side effects ?
15-1	1481-1482	(	_	_	_	_
15-2	1483-1484	(	_	_	_	_
15-3	1485-1487	MM	person	giv	_	_
15-4	1488-1489	)	_	_	_	_
15-5	1490-1491	)	_	_	_	_
15-6	1492-1495	Are	_	_	_	_
15-7	1496-1499	the	_	_	_	_
15-8	1500-1507	current	_	_	_	_
15-9	1508-1516	anti-flu	abstract	new	_	_
15-10	1517-1525	vaccines	substance	new	coref	16-6[87_0]
15-11	1526-1535	effective	_	_	_	_
15-12	1536-1539	and	_	_	_	_
15-13	1540-1543	how	_	_	_	_
15-14	1544-1554	sufficient	_	_	_	_
15-15	1555-1557	is	_	_	_	_
15-16	1558-1561	the	abstract[79]	new[79]	coref	16-13[0_79]
15-17	1562-1569	current	abstract[79]	new[79]	_	_
15-18	1570-1576	supply	abstract[79]	new[79]	_	_
15-19	1577-1578	?	_	_	_	_
15-20	1579-1582	Can	_	_	_	_
15-21	1583-1586	you	person	acc	_	_
15-22	1587-1594	explain	_	_	_	_
15-23	1595-1598	how	_	_	_	_
15-24	1599-1604	these	substance[82]	new[82]	coref	20-5[107_82]
15-25	1605-1615	anti-virus	abstract|substance[82]	new|new[82]	_	_
15-26	1616-1623	vaccine	substance[82]	new[82]	_	_
15-27	1624-1628	work	_	_	_	_
15-28	1629-1632	and	_	_	_	_
15-29	1633-1636	any	abstract[84]	new[84]	coref	23-1[121_84]
15-30	1637-1645	possible	abstract[84]	new[84]	_	_
15-31	1646-1650	side	abstract|abstract[84]	new|new[84]	_	_
15-32	1651-1658	effects	abstract[84]	new[84]	_	_
15-33	1659-1660	?	_	_	_	_

#Text=( ( KM ) ) The current H1N1 vaccines are effective and supply is sufficient .
16-1	1661-1662	(	_	_	_	_
16-2	1663-1664	(	_	_	_	_
16-3	1665-1667	KM	abstract	giv	_	_
16-4	1668-1669	)	_	_	_	_
16-5	1670-1671	)	_	_	_	_
16-6	1672-1675	The	substance[87]	giv[87]	coref	17-5[92_87]
16-7	1676-1683	current	substance[87]	giv[87]	_	_
16-8	1684-1688	H1N1	abstract|substance[87]	giv|giv[87]	coref	17-5
16-9	1689-1697	vaccines	substance[87]	giv[87]	_	_
16-10	1698-1701	are	_	_	_	_
16-11	1702-1711	effective	_	_	_	_
16-12	1712-1715	and	_	_	_	_
16-13	1716-1722	supply	abstract	giv	_	_
16-14	1723-1725	is	_	_	_	_
16-15	1726-1736	sufficient	_	_	_	_
16-16	1737-1738	.	_	_	_	_

#Text=The safety profile of H1N1 vaccines is very good .
17-1	1739-1742	The	abstract[90]	new[90]	_	_
17-2	1743-1749	safety	abstract|abstract[90]	new|new[90]	coref	18-14
17-3	1750-1757	profile	abstract[90]	new[90]	_	_
17-4	1758-1760	of	abstract[90]	new[90]	_	_
17-5	1761-1765	H1N1	abstract[90]|abstract|substance[92]	new[90]|giv|giv[92]	coref|coref	18-9[96_92]|18-9[96_92]
17-6	1766-1774	vaccines	abstract[90]|substance[92]	new[90]|giv[92]	_	_
17-7	1775-1777	is	_	_	_	_
17-8	1778-1782	very	_	_	_	_
17-9	1783-1787	good	_	_	_	_
17-10	1788-1789	.	_	_	_	_

#Text=Outcomes of studies completed to date indicate that pandemic vaccines have a similar safety record as seasonal influenza vaccines .
18-1	1790-1798	Outcomes	abstract[93]	new[93]	_	_
18-2	1799-1801	of	abstract[93]	new[93]	_	_
18-3	1802-1809	studies	abstract[93]|event	new[93]|new	_	_
18-4	1810-1819	completed	_	_	_	_
18-5	1820-1822	to	_	_	_	_
18-6	1823-1827	date	_	_	_	_
18-7	1828-1836	indicate	_	_	_	_
18-8	1837-1841	that	_	_	_	_
18-9	1842-1850	pandemic	plant|substance[96]	giv|giv[96]	coref|coref|coref|coref	19-1|19-1[102_96]|19-1|19-1[102_96]
18-10	1851-1859	vaccines	substance[96]	giv[96]	_	_
18-11	1860-1864	have	_	_	_	_
18-12	1865-1866	a	abstract[98]	new[98]	_	_
18-13	1867-1874	similar	abstract[98]	new[98]	_	_
18-14	1875-1881	safety	abstract|abstract[98]	giv|new[98]	coref	20-2
18-15	1882-1888	record	abstract[98]	new[98]	_	_
18-16	1889-1891	as	abstract[98]	new[98]	_	_
18-17	1892-1900	seasonal	abstract[98]	new[98]	_	_
18-18	1901-1910	influenza	abstract[98]|abstract	new[98]|giv	coref	19-2
18-19	1911-1919	vaccines	abstract[98]	new[98]	_	_
18-20	1920-1921	.	_	_	_	_

#Text=Pandemic influenza vaccines underwent the same production and testing methods as seasonal vaccines .
19-1	1922-1930	Pandemic	person|substance[102]	giv|giv[102]	coref|coref	21-1[113_102]|21-1[113_102]
19-2	1931-1940	influenza	abstract|substance[102]	giv|giv[102]	coref	21-1
19-3	1941-1949	vaccines	substance[102]	giv[102]	_	_
19-4	1950-1959	underwent	_	_	_	_
19-5	1960-1963	the	abstract[103]	new[103]	_	_
19-6	1964-1968	same	abstract[103]	new[103]	_	_
19-7	1969-1979	production	abstract[103]	new[103]	_	_
19-8	1980-1983	and	_	_	_	_
19-9	1984-1991	testing	abstract[104]	new[104]	_	_
19-10	1992-1999	methods	abstract[104]	new[104]	_	_
19-11	2000-2002	as	abstract[104]	new[104]	_	_
19-12	2003-2011	seasonal	abstract[104]	new[104]	_	_
19-13	2012-2020	vaccines	abstract[104]	new[104]	_	_
19-14	2021-2022	.	_	_	_	_

#Text=The safety tracking of the vaccine for adverse events after its distribution and use worldwide has likely been the most thorough and sensitive in history .
20-1	2023-2026	The	abstract[106]	new[106]	_	_
20-2	2027-2033	safety	abstract|abstract[106]	giv|new[106]	_	_
20-3	2034-2042	tracking	abstract[106]	new[106]	_	_
20-4	2043-2045	of	abstract[106]	new[106]	_	_
20-5	2046-2049	the	abstract[106]|substance[107]	new[106]|giv[107]	coref	22-13[120_107]
20-6	2050-2057	vaccine	abstract[106]|substance[107]	new[106]|giv[107]	_	_
20-7	2058-2061	for	abstract[106]|substance[107]	new[106]|giv[107]	_	_
20-8	2062-2069	adverse	abstract[106]|substance[107]|event[108]	new[106]|giv[107]|new[108]	_	_
20-9	2070-2076	events	abstract[106]|substance[107]|event[108]	new[106]|giv[107]|new[108]	_	_
20-10	2077-2082	after	abstract[106]|substance[107]|event[108]	new[106]|giv[107]|new[108]	_	_
20-11	2083-2086	its	abstract[106]|substance[107]|event[108]|abstract[109]	new[106]|giv[107]|new[108]|new[109]	_	_
20-12	2087-2099	distribution	abstract[106]|substance[107]|event[108]|abstract[109]	new[106]|giv[107]|new[108]|new[109]	_	_
20-13	2100-2103	and	_	_	_	_
20-14	2104-2107	use	_	_	_	_
20-15	2108-2117	worldwide	place	new	_	_
20-16	2118-2121	has	_	_	_	_
20-17	2122-2128	likely	_	_	_	_
20-18	2129-2133	been	_	_	_	_
20-19	2134-2137	the	_	_	_	_
20-20	2138-2142	most	_	_	_	_
20-21	2143-2151	thorough	_	_	_	_
20-22	2152-2155	and	_	_	_	_
20-23	2156-2165	sensitive	_	_	_	_
20-24	2166-2168	in	_	_	_	_
20-25	2169-2176	history	abstract	new	_	_
20-26	2177-2178	.	_	_	_	_

#Text=Influenza vaccines cause antibodies to develop in the body .
21-1	2179-2188	Influenza	abstract|substance[113]	giv|giv[113]	coref|coref	24-7[0_113]|24-7[0_113]
21-2	2189-2197	vaccines	substance[113]	giv[113]	_	_
21-3	2198-2203	cause	_	_	_	_
21-4	2204-2214	antibodies	substance	new	coref	22-1[116_0]
21-5	2215-2217	to	_	_	_	_
21-6	2218-2225	develop	_	_	_	_
21-7	2226-2228	in	_	_	_	_
21-8	2229-2232	the	place[115]	new[115]	_	_
21-9	2233-2237	body	place[115]	new[115]	_	_
21-10	2238-2239	.	_	_	_	_

#Text=These antibodies provide protection against infection with the viruses that are in the vaccine .
22-1	2240-2245	These	substance[116]	giv[116]	_	_
22-2	2246-2256	antibodies	substance[116]	giv[116]	_	_
22-3	2257-2264	provide	_	_	_	_
22-4	2265-2275	protection	abstract[117]	new[117]	_	_
22-5	2276-2283	against	abstract[117]	new[117]	_	_
22-6	2284-2293	infection	abstract[117]|event[118]	new[117]|new[118]	_	_
22-7	2294-2298	with	abstract[117]|event[118]	new[117]|new[118]	_	_
22-8	2299-2302	the	abstract[117]|event[118]|object[119]	new[117]|new[118]|giv[119]	coref	24-13[130_119]
22-9	2303-2310	viruses	abstract[117]|event[118]|object[119]	new[117]|new[118]|giv[119]	_	_
22-10	2311-2315	that	_	_	_	_
22-11	2316-2319	are	_	_	_	_
22-12	2320-2322	in	_	_	_	_
22-13	2323-2326	the	substance[120]	giv[120]	coref	23-10[0_120]
22-14	2327-2334	vaccine	substance[120]	giv[120]	_	_
22-15	2335-2336	.	_	_	_	_

#Text=Possible side effects can depend on the type of vaccine , how it is administered and the age of the recipient .
23-1	2337-2345	Possible	abstract[121]	giv[121]	_	_
23-2	2346-2350	side	abstract[121]	giv[121]	_	_
23-3	2351-2358	effects	abstract[121]	giv[121]	_	_
23-4	2359-2362	can	_	_	_	_
23-5	2363-2369	depend	_	_	_	_
23-6	2370-2372	on	_	_	_	_
23-7	2373-2376	the	abstract[122]	new[122]	ana	23-13[0_122]
23-8	2377-2381	type	abstract[122]	new[122]	_	_
23-9	2382-2384	of	abstract[122]	new[122]	_	_
23-10	2385-2392	vaccine	abstract[122]|substance	new[122]|giv	_	_
23-11	2393-2394	,	_	_	_	_
23-12	2395-2398	how	_	_	_	_
23-13	2399-2401	it	abstract	giv	_	_
23-14	2402-2404	is	_	_	_	_
23-15	2405-2417	administered	_	_	_	_
23-16	2418-2421	and	_	_	_	_
23-17	2422-2425	the	abstract[125]	giv[125]	_	_
23-18	2426-2429	age	abstract[125]	giv[125]	_	_
23-19	2430-2432	of	abstract[125]	giv[125]	_	_
23-20	2433-2436	the	abstract[125]|person[126]	giv[125]|new[126]	_	_
23-21	2437-2446	recipient	abstract[125]|person[126]	giv[125]|new[126]	_	_
23-22	2447-2448	.	_	_	_	_

#Text=There are two main types of vaccines : one is manufactured with inactivated viruses , the other uses live viruses .
24-1	2449-2454	There	_	_	_	_
24-2	2455-2458	are	_	_	_	_
24-3	2459-2462	two	place[127]	new[127]	_	_
24-4	2463-2467	main	place[127]	new[127]	_	_
24-5	2468-2473	types	place[127]	new[127]	_	_
24-6	2474-2476	of	place[127]	new[127]	_	_
24-7	2477-2485	vaccines	place[127]|substance	new[127]|giv	coref	25-1[132_0]
24-8	2486-2487	:	_	_	_	_
24-9	2488-2491	one	abstract	new	_	_
24-10	2492-2494	is	_	_	_	_
24-11	2495-2507	manufactured	_	_	_	_
24-12	2508-2512	with	_	_	_	_
24-13	2513-2524	inactivated	object[130]	giv[130]	_	_
24-14	2525-2532	viruses	object[130]	giv[130]	_	_
24-15	2533-2534	,	object[130]	giv[130]	_	_
24-16	2535-2538	the	object[130]|abstract[131]	giv[130]|new[131]	_	_
24-17	2539-2544	other	object[130]|abstract[131]	giv[130]|new[131]	_	_
24-18	2545-2549	uses	object[130]|abstract[131]	giv[130]|new[131]	_	_
24-19	2550-2554	live	object[130]	giv[130]	_	_
24-20	2555-2562	viruses	object[130]	giv[130]	_	_
24-21	2563-2564	.	_	_	_	_

#Text=Inactivated vaccines , administered by injection , commonly cause local reactions such as soreness , swelling and redness at the injection site , and less often can cause fever , muscle- or joint- aches or headache .
25-1	2565-2576	Inactivated	substance[132]	giv[132]	_	_
25-2	2577-2585	vaccines	substance[132]	giv[132]	_	_
25-3	2586-2587	,	_	_	_	_
25-4	2588-2600	administered	_	_	_	_
25-5	2601-2603	by	_	_	_	_
25-6	2604-2613	injection	event	new	coref	25-21
25-7	2614-2615	,	_	_	_	_
25-8	2616-2624	commonly	_	_	_	_
25-9	2625-2630	cause	_	_	_	_
25-10	2631-2636	local	event[134]	new[134]	_	_
25-11	2637-2646	reactions	event[134]	new[134]	_	_
25-12	2647-2651	such	event[134]	new[134]	_	_
25-13	2652-2654	as	event[134]	new[134]	_	_
25-14	2655-2663	soreness	event[134]|abstract	new[134]|new	_	_
25-15	2664-2665	,	event[134]	new[134]	_	_
25-16	2666-2674	swelling	event[134]|abstract	new[134]|new	_	_
25-17	2675-2678	and	event[134]	new[134]	_	_
25-18	2679-2686	redness	event[134]|abstract[137]	new[134]|new[137]	_	_
25-19	2687-2689	at	event[134]|abstract[137]	new[134]|new[137]	_	_
25-20	2690-2693	the	event[134]|abstract[137]|place[139]	new[134]|new[137]|new[139]	_	_
25-21	2694-2703	injection	event[134]|abstract[137]|event|place[139]	new[134]|new[137]|giv|new[139]	_	_
25-22	2704-2708	site	event[134]|abstract[137]|place[139]	new[134]|new[137]|new[139]	_	_
25-23	2709-2710	,	_	_	_	_
25-24	2711-2714	and	_	_	_	_
25-25	2715-2719	less	_	_	_	_
25-26	2720-2725	often	_	_	_	_
25-27	2726-2729	can	_	_	_	_
25-28	2730-2735	cause	_	_	_	_
25-29	2736-2741	fever	substance	new	coref	27-1
25-30	2742-2743	,	_	_	_	_
25-31	2744-2751	muscle-	abstract	new	_	_
25-32	2752-2754	or	_	_	_	_
25-33	2755-2761	joint-	abstract[142]	new[142]	coref	27-3[0_142]
25-34	2762-2767	aches	abstract[142]	new[142]	_	_
25-35	2768-2770	or	_	_	_	_
25-36	2771-2779	headache	abstract	new	_	_
25-37	2780-2781	.	_	_	_	_

#Text=These symptoms are generally mild , do not need medical attention , and last 1 to 2 days .
26-1	2782-2787	These	abstract[144]	new[144]	_	_
26-2	2788-2796	symptoms	abstract[144]	new[144]	_	_
26-3	2797-2800	are	_	_	_	_
26-4	2801-2810	generally	_	_	_	_
26-5	2811-2815	mild	_	_	_	_
26-6	2816-2817	,	_	_	_	_
26-7	2818-2820	do	_	_	_	_
26-8	2821-2824	not	_	_	_	_
26-9	2825-2829	need	_	_	_	_
26-10	2830-2837	medical	abstract[145]	new[145]	_	_
26-11	2838-2847	attention	abstract[145]	new[145]	_	_
26-12	2848-2849	,	_	_	_	_
26-13	2850-2853	and	_	_	_	_
26-14	2854-2858	last	time[146]	new[146]	_	_
26-15	2859-2860	1	time[146]	new[146]	_	_
26-16	2861-2863	to	time[146]	new[146]	_	_
26-17	2864-2865	2	time[146]|time[147]	new[146]|new[147]	_	_
26-18	2866-2870	days	time[146]|time[147]	new[146]|new[147]	_	_
26-19	2871-2872	.	_	_	_	_

#Text=Fever , aches and headaches can occur more frequently in children compared to elderly people .
27-1	2873-2878	Fever	abstract	giv	_	_
27-2	2879-2880	,	_	_	_	_
27-3	2881-2886	aches	abstract	giv	_	_
27-4	2887-2890	and	_	_	_	_
27-5	2891-2900	headaches	abstract	new	_	_
27-6	2901-2904	can	_	_	_	_
27-7	2905-2910	occur	_	_	_	_
27-8	2911-2915	more	_	_	_	_
27-9	2916-2926	frequently	_	_	_	_
27-10	2927-2929	in	_	_	_	_
27-11	2930-2938	children	person	new	_	_
27-12	2939-2947	compared	_	_	_	_
27-13	2948-2950	to	_	_	_	_
27-14	2951-2958	elderly	person[152]	giv[152]	_	_
27-15	2959-2965	people	person[152]	giv[152]	_	_
27-16	2966-2967	.	_	_	_	_
